Clinical trial
Dose Finding Study in COPD
NCT00122434 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00122434 |
|---|---|
| Title | Dose Finding Study in COPD |
| Official title | A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | BEA 2180 BR, tiotropium |
| Enrollment | 389 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2006 |
| First posted | Jul 22, 2005 |
| Last update posted | Dec 28, 2017 |
| Countries | Belgium, Netherlands, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: